10 IO topics to watch out for at ASH23
Finding the sweetspot in early stage cancer drug development
A look at some cool science and novel strategies for tackling an intractable target
Can a genomic signature help select patients more accurately for DDR therapies?
What are Novartis up to these days with their oncology pipeline and what are they excited about?
A look at why and how Relay's early oncology pipeline might be one to reckon with
Update on the T cell engager niche with an emerging agent of interest
A careful look at what we can learn from the Beigene anti-TIGIT data for ociperlimab
Do we need to target the adenosine fog as well as TIGIT in NSCLC?
A look at 6 IO products in the Heme space and what to watch out for.
Update on the Novartis SHP2 inhibitor at ASCO21
New product development and early phase anti-cancer agents have been very much a focus on BSB (and PSB…
A look at what's happening in RCC and what to watch out for at ASCO this year
PARP inhibitors move into the adjuvant setting at long last? Say it ain't so!
A look at the first anti-cancer therapy with a radiopharmaceutical in advanced prostate cancer
A look at some hidden gems in the ASCO program and what it all means in terms of the science.
Hidden early stage gems to watch out for at ASCO21
Which abstracts stood out in the initial run through of the data? Includes some hidden gems and surprises!
Going beyond the obvious conclusion with anti-LAG3 therapy
New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.
Some key learnings from the ESMO Breast Cancer meeting held last week
Bridging the DDR gap from AACR to ASCO
